Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Community Stories
DMD
DM1
Careers
Investors
News
Contact
Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Post navigation
Previous:
PGN-EDODM1 Nonclinical Data Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of Myotonic Dystrophy Type 1 (DM1)
Next:
FREEDOM-DM1: Nonclinical Data Support the Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1)
